Menu ×

HEALTHCARE & PHARMACEUTICAL

Non-Cancerous Blood Disease Market Segmentation by Disorder Type (Bleeding, Platelet, White Blood Cell, Plasma Cell, Rare Hematological, and Spleen Disorders, and Anemia); by Treatment Type (Antibiotics, Blood Transfusion, Infusion Therapy, Dietary Supplements or Chelators, and Others); by Gender (Male, and Female); by End-User (Hospitals, Clinics, and Others) – Global Demand Analysis & Opportunity Outlook 2021-2031

  • Text Size:

Extensive insights into the Growth of Non-Cancerous Blood Disease Market amidst COVID-19

Get the detailed impact analysis of COVID-19 that has disrupted the entire world and affected many industries.

Request Insights


IN THE NEWS

  • February 4th, 2022: SANOFI announced that it has received approval for Enjaymo, the first and only approved treatment for use in patients with cold agglutinin disease, by the United States Food and Drug Administration (FDA).

  • November 5th, 2020: CSL Behring announced that it has received Marketing Authorization Application (MAA) by the chief scientific body of the European Medicines Agency (EMA), the Committee for Medicinal Products for Human Use (CHMP), for its investigational gene therapy, etranacogene dezaparvovec, also known as EtranaDez, applicable for people living with the life-threatening bleeding disorder, hemophilia B.

Global Non-Cancerous Blood Disease Market Highlights Over 2021 - 2031

The global non-cancerous blood disease market is estimated to garner a revenue of USD 105972.8 Million by the end of 2031, by growing at a CAGR of 6.40% over the forecast period, i.e., 2022 – 2031. Moreover, the market registered a revenue of USD 57224.1 Million in the year 2021. The growth of the market can be attributed to the growing prevalence of several non-cancerous blood disorders, such as hemoglobinopathies, platelet & coagulation related disorders, anemia, sickle cell disease, hemophilia, and thalassemia among others. For instance, according to the statistics by the World Health Organization (WHO), in the year 2019, the global prevalence of anemia recorded to be 29.9% in women of reproductive age, 29.6% in non-pregnant women of reproductive age, and 36.5% in pregnant women. Additionally, in children between the ages 6 and 59 months, the prevalence of the disease in the same year was 39.8%.

Non-Cancerous Blood Disease Market Graph

Get more information on this report: Request Sample PDF

The market growth can also be attributed to the growing burden of hemoglobinopathies, backed by the increasing migration of population to higher-income countries from low- as well as middle-income nations. The human migration is expected to continue at an increasing rate amid globalization. Consequently, the number of hemoglobinopathies immigrants is also expected to grow, supported by population growth and transition to public health. Besides this, the increasing need for early diagnosis of these diseases, followed by the rapid advancements in the development of orphan drugs, along with the emerging research activities in the development of advanced drugs and therapies are also expected to boost the market growth in the coming years.

Global Non-Cancerous Blood Disease Market Regional Synopsis

Regionally, the global non-cancerous blood disease market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in Europe region is anticipated to garner the largest revenue of USD 39845.4 Million by the end of 2031, up from a revenue of USD 21344.6 Million in the year 2021. The growth of the market in the region can primarily be attributed to the growing awareness for non-cancerous blood diseases, along with the rising concern for the increasing economic burden of non-malignant blood disorders. Besides this, the increasing prevalence of these diseases is also expected to contribute to the market growth in the coming years. According to the World Bank, the prevalence of anemia among children (% of children ages 6-59 months) in the European Union increased from 13.86% in the year 2007 to 16.084% in the year 2019.

The market in the region is further segmented by country into Germany, United Kingdom, Italy, France, Russia, and the Rest of Europe. The market in Germany is anticipated to garner the second-largest revenue of USD 7736.2 Million by the end of 2031, up from a revenue of USD 3863.4 Million in the year 2021.

The study further incorporates Y-O-Y Growth, market opportunities, demand & supply and forecast future opportunity in North America (United States, Canada, Mexico), South America, Europe (U.K., Germany, France, Italy, Spain, Hungary, BENELUX [Belgium, Netherlands, Luxembourg], NORDIC [Norway, Denmark, Sweden, Finland], Poland, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Indonesia, Taiwan, Hong Kong, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).

Growth Drivers and Challenges Impacting the Growth of the Global Non-Cancerous Blood Disease Market

Growth Drivers

  • Increasing Prevalence of Various Non-Cancerous Blood Disorders
  • Growing Number of Hemoglobinopathies Immigrants
  • Escalating Need for Early Diagnosis of Diseases

Challenges

  • High Cost of Treatment of These Diseases
  • Complexities in Monitoring Several Non-Malignant Blood Disorders

Global Non-Cancerous Blood Disease Market Segmentation Synopsis

The global non-cancerous blood disease market is segmented by disorder type into anemia, bleeding disorders, platelet disorders, white blood cell disorders, plasma cell disorders, rare hematological disorders, and spleen disorders. Out of these, the bleeding disorders segment is projected to display the largest revenue of USD 29949.69 Million by the end of 2031, up from a revenue of USD 16570.67 Million in the year 2021. By treatment type, the market is segmented into antibiotics, blood transfusion, infusion therapy, dietary supplements or chelators, and others. Out of these, the blood transfusion segment is anticipated to garner the second-largest revenue of USD 22268.46 Million by the end of 2031, up from a revenue of USD 12120.08 Million in the year 2021. By gender, the market is segmented into male, and female, out of which, the female segment is projected to garner the highest market share by the end of 2031. By end-user, the market is segmented into hospitals, clinics, and others. Out of these, the hospitals segment is anticipated to garner the largest revenue of USD 57466.34 Million by the end of 2031, up from a revenue of USD 31059.08 Million in the year 2021.

Key Companies Dominating the Market

Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global non-cancerous blood disease market that are included in our report are SANOFI, Novo Nordisk A/S, Novartis AG, Pfizer Inc., Amgen Inc., Alexion Pharmaceuticals, Inc., Bayer AG, Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., Takeda Pharmaceutical Company Limited, CSL Behring, and others.

Key Reasons to Buy Our Report

  • The report covers detailed analysis comprising market share attained by each market segment and its sub-segments.
  • It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis and challenges that impact the market growth.
  • The report includes detailed company profiles of the major players dominating the market.
  • We use effective research methodologies to calculate the market numbers and provide value-added assessment for overall growth.
  • We provide customized reports as per the clients’ requirement helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goal.

FREQUENTLY ASKED QUESTIONS

  1. Market Definition and Research Methodology
    1. Market Definition and Segmentation
    2. Assumptions and Acronyms
    3. Research Objective
    4. Research Methodology
  2. Executive Summary
  3. Market Dynamics
    1. Growth Drivers
    2. Market Trends
  4. Key Market Opportunities
  5. Major Roadblocks for the Market Growth
  6. Regulatory & Standards Landscape
  7. Industry Risk Analysis
  8. Analysis on Treatment Type
  9. Epidemiology Analysis
  10. R&D Pipeline Analysis
  11. Proportion of Healthcare Expenditure (%) by Category and Blood Disorder Type, 2021
  12. Analysis on the Existing Drug in the Market
  13. Competitive Positioning
  14. Competitive Structure
    1. SANOFI
    2. Novo Nordisk A/S
    3. Novartis AG
    4. Pfizer Inc.
    5. Amgen Inc.
    6. Alexion Pharmaceuticals, Inc.
    7. Bayer AG
    8. Bristol Myers Squibb Company
    9. F. Hoffmann-La Roche Ltd.
    10. Takeda Pharmaceutical Company Limited
    11. CSL Behring
  15. Global Non-Cancerous Blood Disease Market
    1. By Value (USD Million)
    2. Market Segmentation Analysis 2021-2031
      1. By Disorder Type
        1. Anemia, 2021-2031F (USD Million)
          1. Aplastic Anemia, 2021-2031F (USD Million)
          2. Hemolytic Anemia, 2021-2031F (USD Million)
          3. Iron Deficiency Anemia, 2021-2031F (USD Million)
          4. Sickle Cell Anemia, 2021-2031F (USD Million)
          5. Others, 2021-2031F (USD Million)
        2. Bleeding Disorders, 2021-2031F (USD Million)
          1. Hemophilia, 2021-2031F (USD Million)
          2. Von Willebrand Disease, 2021-2031F (USD Million)
          3. Others, 2021-2031F (USD Million)
        3. Platelet Disorders, 2021-2031F (USD Million)
          1. Autoimmune Thrombocytopenia, 2021-2031F (USD Million)
          2. Thrombocytopenia, 2021-2031F (USD Million)
          3. Thrombocytosis, 2021-2031F (USD Million)
          4. Others, 2021-2031F (USD Million)
        4. White Blood Cell Disorders, 2021-2031F (USD Million)
          1. Basophilic Disorders, 2021-2031F (USD Million)
          2. Lymphocytopenia, 2021-2031F (USD Million)
          3. Neutropenia, 2021-2031F (USD Million)
          4. Systemic Mastocytosis, 2021-2031F (USD Million)
          5. Others, 2021-2031F (USD Million)
        5. Plasma Cell Disorders, 2021-2031F (USD Million)
          1. Macroglobulinemia, 2021-2031F (USD Million)
          2. POEMS Syndrome, 2021-2031F (USD Million)
          3. Cryoglobulinemia, 2021-2031F (USD Million)
          4. Others, 2021-2031F (USD Million)
        6. Rare Hematological Disorders, 2021-2031F (USD Million)
          1. Amyloidosis, 2021-2031F (USD Million)
          2. Castleman Disease, 2021-2031F (USD Million)
          3. Paroxysmal Nocturnal Hemoglobinuria, 2021-2031F (USD Million)
          4. Others, 2021-2031F (USD Million)
        7. Spleen Disorders, 2021-2031F (USD Million)
      2. By Treatment Type
        1. Antibiotics, 2021-2031F (USD Million)
        2. Blood Transfusion, 2021-2031F (USD Million)
        3. Infusion Therapy, 2021-2031F (USD Million)
        4. Dietary Supplements or Chelators, 2021-2031F (USD Million)
        5. Others, 2021-2031F (USD Million)
      3. By Gender
        1. Male, 2021-2031F (USD Million)
        2. Female, 2021-2031F (USD Million)
      4. By End-User
        1. Hospitals, 2021-2031F (USD Million)
        2. Clinics, 2021-2031F (USD Million)
        3. Others, 2021-2031F (USD Million)
      5. By Region
        1. North America, 2021-2031F (USD Million)
        2. Europe, 2021-2031F (USD Million)
        3. Asia Pacific, 2021-2031F (USD Million)
        4. Latin America, 2021-2031F (USD Million)
        5. Middle East & Africa, 2021-2031F (USD Million)
  16. North America Non-Cancerous Blood Disease Market
    1. By Value (USD Million)
    2. Market Segmentation Analysis 2021-2031
      1. By Disorder Type
        1. Anemia, 2021-2031F (USD Million)
          1. Aplastic Anemia, 2021-2031F (USD Million)
          2. Hemolytic Anemia, 2021-2031F (USD Million)
          3. Iron Deficiency Anemia, 2021-2031F (USD Million)
          4. Sickle Cell Anemia, 2021-2031F (USD Million)
          5. Others, 2021-2031F (USD Million)
        2. Bleeding Disorders, 2021-2031F (USD Million)
          1. Hemophilia, 2021-2031F (USD Million)
          2. Von Willebrand Disease, 2021-2031F (USD Million)
          3. Others, 2021-2031F (USD Million)
        3. Platelet Disorders, 2021-2031F (USD Million)
          1. Autoimmune Thrombocytopenia, 2021-2031F (USD Million)
          2. Thrombocytopenia, 2021-2031F (USD Million)
          3. Thrombocytosis, 2021-2031F (USD Million)
          4. Others, 2021-2031F (USD Million)
        4. White Blood Cell Disorders, 2021-2031F (USD Million)
          1. Basophilic Disorders, 2021-2031F (USD Million)
          2. Lymphocytopenia, 2021-2031F (USD Million)
          3. Neutropenia, 2021-2031F (USD Million)
          4. Systemic Mastocytosis, 2021-2031F (USD Million)
          5. Others, 2021-2031F (USD Million)
        5. Plasma Cell Disorders, 2021-2031F (USD Million)
          1. Macroglobulinemia, 2021-2031F (USD Million)
          2. POEMS Syndrome, 2021-2031F (USD Million)
          3. Cryoglobulinemia, 2021-2031F (USD Million)
          4. Others, 2021-2031F (USD Million)
        6. Rare Hematological Disorders, 2021-2031F (USD Million)
          1. Amyloidosis, 2021-2031F (USD Million)
          2. Castleman Disease, 2021-2031F (USD Million)
          3. Paroxysmal Nocturnal Hemoglobinuria, 2021-2031F (USD Million)
          4. Others, 2021-2031F (USD Million)
        7. Spleen Disorders, 2021-2031F (USD Million)
      2. By Treatment Type
        1. Antibiotics, 2021-2031F (USD Million)
        2. Blood Transfusion, 2021-2031F (USD Million)
        3. Infusion Therapy, 2021-2031F (USD Million)
        4. Dietary Supplements or Chelators, 2021-2031F (USD Million)
        5. Others, 2021-2031F (USD Million)
      3. By Gender
        1. Male, 2021-2031F (USD Million)
        2. Female, 2021-2031F (USD Million)
      4. By End-User
        1. Hospitals, 2021-2031F (USD Million)
        2. Clinics, 2021-2031F (USD Million)
        3. Others, 2021-2031F (USD Million)
      5. By Country
        1. United States, 2021-2031F (USD Million)
        2. Canada, 2021-2031F (USD Million)
  17. Europe Non-Cancerous Blood Disease Market
    1. By Value (USD Million)
    2. Market Segmentation Analysis 2021-2031
      1. By Disorder Type
      2. By Treatment Type
      3. By Gender
      4. By End-User
      5. By Country
        1. United Kingdom, 2021-2031F (USD Million)
        2. Germany, 2021-2031F (USD Million)
        3. Italy, 2021-2031F (USD Million)
        4. France, 2021-2031F (USD Million)
        5. Russia, 2021-2031F (USD Million)
        6. Rest of Europe, 2021-2031F (USD Million)
  18. Asia Pacific Non-Cancerous Blood Disease Market
    1. By Value (USD Million)
    2. Market Segmentation Analysis 2021-2031
      1. By Disorder Type
      2. By Treatment Type
      3. By Gender
      4. By End-User
      5. By Country
        1. China, 2021-2031F (USD Million)
        2. Japan, 2021-2031F (USD Million)
        3. Singapore, 2021-2031F (USD Million)
        4. South Korea, 2021-2031F (USD Million)
        5. India, 2021-2031F (USD Million)
        6. Australia, 2021-2031F (USD Million)
        7. Rest of APAC, 2021-2031F (USD Million)
  19. Latin America Non-Cancerous Blood Disease Market
    1. By Value (USD Million)
    2. Market Segmentation Analysis 2021-2031
      1. By Disorder Type
      2. By Treatment Type
      3. By Gender
      4. By End-User
      5. By Country
        1. Brazil, 2021-2031F (USD Million)
        2. Argentina, 2021-2031F (USD Million)
        3. Mexico, 2021-2031F (USD Million)
        4. Rest of LATAM, 2021-2031F (USD Million)
  20. Middle East & Africa Non-Cancerous Blood Disease Market
    1. By Value (USD Million)
    2. Market Segmentation Analysis 2021-2031
      1. By Disorder Type
      2. By Treatment Type
      3. By Gender
      4. By End-User
      5. By Country
        1. GCC, 2021-2031F (USD Million)
        2. Israel, 2021-2031F (USD Million)
        3. South Africa, 2021-2031F (USD Million)
        4. Rest of MEA, 2021-2031F (USD Million)
  21. Primary Interview Analysis
  22. Secondary Research Analysis
  23. Methodology: Global Non-Cancerous Blood Disease Market

Related Reports


Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved